Hospital & Healthcare Services · Founded 1989 · www.fortismalarhospital.com · BSE 523696 · · ISIN INE842B01015
No Notes Added Yet
Business
Fortis Malar Hospitals Ltd. operates as a multi-specialty hospital in India, primarily based in Chennai. The company is engaged in providing comprehensive healthcare services, including medical, surgical, diagnostic, and emergency care across various specialties. Its core business model revolves around generating revenue from patient services, which includes consultation fees, inpatient charges, surgical procedures, diagnostic tests, pharmacy sales, and other allied healthcare services, often reimbursed through direct patient payments or health insurance providers.
Revenue Mix
The primary revenue segment for Fortis Malar Hospitals is its hospital services, encompassing a wide range of medical specialties such such as cardiology, orthopedics, neurology, gastroenterology, oncology, and critical care. As specific financial breakdowns are not publicly available from the provided data, a detailed percentage contribution of each specialty or service line cannot be provided. However, like most multi-specialty hospitals, its revenue mix would typically be diversified across inpatient and outpatient services, with a significant portion derived from complex surgical procedures and long-term care for critical illnesses.
Industry
The Indian hospital and healthcare services industry is characterized by strong growth, driven by increasing healthcare expenditure, a rising burden of lifestyle diseases, improving health insurance penetration, and a growing medical tourism sector. The industry is fragmented but consolidating, with large corporate hospital chains playing an increasingly dominant role. Fortis Malar, as part of the broader Fortis Healthcare network (now majority-owned by IHH Healthcare Berhad), benefits from the established brand recognition and operational scale of one of India's largest private hospital groups. It is positioned as a provider of tertiary and quaternary care, often competing with other major corporate hospital chains and standalone specialized hospitals in its operating region.
MOAT
Brand Reputation: Being part of the "Fortis" brand provides a significant advantage in terms of patient trust and recognition, which is critical in healthcare.
Network & Scale: Access to the broader Fortis Healthcare network can provide benefits in terms of procurement, cross-referrals, and shared best practices.
Specialized Expertise: Investment in advanced medical technology and attracting highly skilled medical professionals in various specialties can create a competitive edge for complex procedures.
Established Infrastructure: An existing, well-equipped hospital facility in a prime location offers a barrier to entry for new competitors.
Growth Drivers
Increasing Healthcare Demand: Rising disposable incomes, greater health awareness, and the increasing incidence of chronic and lifestyle diseases will continue to drive demand for quality healthcare services.
Health Insurance Penetration: Growing adoption of government (e.g., Ayushman Bharat) and private health insurance schemes expands access to corporate healthcare.
Medical Tourism: India's attractiveness as a hub for cost-effective, high-quality medical treatment can contribute to patient inflow.
Technological Advancements: Adoption of new medical technologies, minimally invasive procedures, and digital health solutions can enhance service offerings and efficiency.
Aging Population: The demographic shift towards an older population creates a sustained demand for healthcare services.
Risks
Regulatory Risks: Government interventions such as price caps on medical procedures, drugs, or medical devices can impact profitability. Changes in healthcare policies or taxation can also pose risks.
Intense Competition: The Indian healthcare market is highly competitive, with numerous private players, which can lead to pricing pressures and challenges in patient acquisition.
Talent Retention: Shortage of skilled medical professionals (doctors, nurses, technicians) and high attrition rates can lead to increased operational costs and impact service quality.
Operational Costs: High costs associated with advanced medical equipment, maintenance, medical supplies, power, and human resources can impact margins.
Reputational Risks: Any adverse events, medical errors, or negative publicity can severely damage patient trust and impact business.
Management & Ownership
Fortis Malar Hospitals Ltd. is closely associated with Fortis Healthcare Limited. Fortis Healthcare has undergone significant changes in promoter ownership and management in recent years, with IHH Healthcare Berhad (a Malaysian healthcare conglomerate) now being the largest shareholder. This has led to a restructuring of the board and management at the group level, aiming to improve corporate governance and operational efficiency. Specific details on the management team dedicated solely to Fortis Malar are not widely publicized, but it operates under the broader strategic direction and operational frameworks set by Fortis Healthcare and IHH.
Outlook
Fortis Malar Hospitals operates in a structurally growing sector driven by India's demographic trends and increasing healthcare needs. The hospital benefits from the established brand equity of Fortis and the strategic backing of IHH Healthcare, which could provide capital for expansion and operational expertise. However, the outlook is balanced by significant challenges including intense competition, the potential for regulatory pressures on pricing, and the continuous need for investment in technology and human capital. Success will depend on its ability to maintain high service quality, manage operational costs effectively, and navigate the evolving regulatory landscape while leveraging its brand strength within its specific geographic market.
Price goes above X
Price falls below X
PE goes above X
PE falls below X
| #(Fig in Cr.) | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income | 2 | 1 | 1 | 1 | 1 | 5 | 1 | 1 | 1 | 1 |
| Total Income | 7 | 1 | 1 | 1 | 1 | 5 | 1 | 1 | 1 | 1 |
| Total Expenditure | 5 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Operating Profit | 2 | -0 | 0 | 0 | 0 | 4 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exceptional Income / Expenses | 58 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 59 | -0 | 0 | 0 | 0 | 4 | 0 | 0 | 0 | 0 |
| Provision for Tax | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Tax | 54 | -0 | 0 | 0 | 0 | 4 | 0 | 0 | -0 | 0 |
| Adjustments | 0 | 0 | -0 | 0 | 0 | 0 | 0 | -0 | 0 | -0 |
| Profit After Adjustments | 54 | -0 | 0 | 0 | 0 | 4 | 0 | 0 | -0 | 0 |
| Adjusted Earnings Per Share | 28.8 | -0 | 0 | 0 | 0.2 | 2.2 | 0 | 0 | -0 | 0.1 |
| #(Fig in Cr.) | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 130 | 141 | 149 | 145 | 112 | 69 | 86 | 86 | 59 | 0 | 0 | 0 |
| Other Income | 9 | 8 | 8 | 10 | 11 | 8 | 7 | 7 | 7 | 3 | 6 | 4 |
| Total Income | 138 | 149 | 158 | 155 | 123 | 77 | 94 | 93 | 66 | 3 | 6 | 4 |
| Total Expenditure | 124 | 140 | 147 | 147 | 115 | 76 | 83 | 81 | 60 | 2 | 2 | 1 |
| Operating Profit | 14 | 9 | 10 | 8 | 8 | 2 | 11 | 11 | 6 | 1 | 5 | 0 |
| Interest | 0 | 0 | 0 | 1 | 8 | 7 | 7 | 6 | 4 | 0 | 0 | 0 |
| Depreciation | 3 | 4 | 4 | 4 | 13 | 13 | 13 | 12 | 9 | 0 | 0 | 0 |
| Exceptional Income / Expenses | -1 | 0 | 0 | 0 | 0 | 7 | 0 | 0 | 58 | 0 | 0 | 0 |
| Profit Before Tax | 10 | 4 | 6 | 3 | -12 | -11 | -8 | -7 | 50 | 1 | 5 | 0 |
| Provision for Tax | 4 | 1 | 2 | 1 | -3 | -3 | 0 | 8 | 5 | 0 | 1 | 0 |
| Profit After Tax | 6 | 3 | 3 | 2 | -9 | -8 | -8 | -15 | 45 | 0 | 4 | 0 |
| Adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | 6 | 3 | 3 | 2 | -9 | -8 | -8 | -15 | 45 | 0 | 4 | 0 |
| Adjusted Earnings Per Share | 3.4 | 1.7 | 1.8 | 1.1 | -4.7 | -4.2 | -4.4 | -8.3 | 24.2 | 0.2 | 2.2 | 0.1 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 0% | -100% | -100% | -100% |
| Operating Profit CAGR | 400% | -23% | 20% | -10% |
| PAT CAGR | 0% | 0% | 0% | -4% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | -37% | -10% | -9% | -7% |
| ROE Average | 13% | 22% | 7% | 3% |
| ROCE Average | 15% | 26% | 15% | 8% |
| #(Fig in Cr.) | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 98 | 100 | 103 | 105 | 96 | 89 | 80 | 64 | 109 | 30 | 34 |
| Minority's Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Borrowings | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | -0 | -0 | -0 | 56 | 47 | 41 | 42 | 0 | 0 | 0 |
| Total Current Liabilities | 32 | 30 | 45 | 44 | 36 | 25 | 31 | 32 | 6 | 7 | 3 |
| Total Liabilities | 130 | 130 | 148 | 149 | 188 | 161 | 152 | 138 | 116 | 37 | 38 |
| Fixed Assets | 25 | 25 | 24 | 22 | 81 | 69 | 58 | 47 | 0 | 0 | 0 |
| Other Non-Current Assets | 3 | 8 | 11 | 15 | 45 | 32 | 46 | 6 | 3 | 3 | 1 |
| Total Current Assets | 102 | 97 | 113 | 112 | 62 | 60 | 49 | 84 | 113 | 34 | 37 |
| Total Assets | 130 | 130 | 148 | 149 | 188 | 161 | 152 | 138 | 116 | 37 | 38 |
| #(Fig in Cr.) | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 16 | 3 | 7 | 15 | 5 | 43 | 7 | 12 | 6 | 107 | 0 |
| Cash Flow from Operating Activities | 10 | -9 | 9 | -16 | -0 | -1 | 7 | 6 | -7 | 2 | 1 |
| Cash Flow from Investing Activities | -22 | 13 | -2 | 6 | 50 | -28 | 8 | 0 | 120 | -29 | 0 |
| Cash Flow from Financing Activities | -1 | -1 | 0 | 0 | -12 | -7 | -10 | -13 | -11 | -80 | 0 |
| Net Cash Inflow / Outflow | -13 | 4 | 7 | -9 | 38 | -36 | 5 | -7 | 102 | -107 | 1 |
| Closing Cash & Cash Equivalent | 3 | 7 | 15 | 5 | 43 | 7 | 12 | 6 | 107 | 0 | 1 |
| # | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 3.45 | 1.67 | 1.78 | 1.1 | -4.75 | -4.2 | -4.41 | -8.26 | 24.18 | 0.21 | 2.21 |
| CEPS(Rs) | 5.15 | 3.78 | 4.03 | 3.44 | 1.94 | 2.67 | 2.27 | -1.78 | 29.18 | 0.21 | 2.21 |
| DPS(Rs) | 0.5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 42.5 | 0 |
| Book NAV/Share(Rs) | 52.47 | 53.33 | 55.14 | 56.22 | 51.43 | 47.34 | 42.75 | 34.23 | 58.4 | 16.11 | 18.32 |
| Core EBITDA Margin(%) | 4 | 0.64 | 1.17 | -1.68 | -2.49 | -9.15 | 3.99 | 5.32 | -2.04 | 0 | -3083.76 |
| EBIT Margin(%) | 7.99 | 3.51 | 4.01 | 2.28 | -3.69 | -5.94 | -1.98 | -1.09 | 92.04 | 0 | 9248.53 |
| Pre Tax Margin(%) | 7.68 | 3.18 | 3.75 | 1.93 | -10.67 | -16.34 | -9.59 | -8.15 | 84.75 | 0 | 9248.53 |
| PAT Margin (%) | 4.95 | 2.22 | 2.23 | 1.42 | -7.95 | -11.36 | -9.6 | -18.01 | 76.81 | 0 | 8096.67 |
| Cash Profit Margin (%) | 7.39 | 5.02 | 5.05 | 4.45 | 3.25 | 7.23 | 4.94 | -3.88 | 92.67 | 0 | 8096.67 |
| ROA(%) | 4.97 | 2.4 | 2.4 | 1.39 | -5.27 | -4.51 | -5.29 | -10.66 | 35.71 | 0.51 | 11.12 |
| ROE(%) | 6.8 | 3.16 | 3.28 | 1.97 | -8.82 | -8.5 | -9.8 | -21.46 | 52.21 | 0.56 | 12.82 |
| ROCE(%) | 10.96 | 5 | 5.9 | 3.17 | -4.09 | -4.44 | -2.02 | -1.3 | 62.56 | 0.83 | 14.64 |
| Receivable days | 14.4 | 15.05 | 14.17 | 19.77 | 21.84 | 15.34 | 9.09 | 11.43 | 0 | 0 | 0 |
| Inventory Days | 5.09 | 6.39 | 5.3 | 4.63 | 4.82 | 7.73 | 7.39 | 6.3 | 0 | 0 | 0 |
| Payable days | 229.91 | 216.62 | 216.82 | 265.9 | 363.31 | 432.03 | 368.49 | 580.35 | 530.18 | 0 | 0 |
| PER(x) | 16.08 | 41.92 | 32.68 | 50.15 | 0 | 0 | 0 | 0 | 1.93 | 350.91 | 18.88 |
| Price/Book(x) | 1.06 | 1.31 | 1.05 | 0.98 | 0.84 | 1.17 | 1.35 | 1.39 | 0.8 | 4.56 | 2.28 |
| Dividend Yield(%) | 0.9 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 57.89 | 0 |
| EV/Net Sales(x) | 0.6 | 0.87 | 0.63 | 0.67 | 0.33 | 1.3 | 1.11 | 0.93 | -0.35 | 0 | 1045.69 |
| EV/Core EBITDA(x) | 5.55 | 13.86 | 9.21 | 12.55 | 4.44 | 47.21 | 8.82 | 7.13 | -3.63 | 207.14 | 11.31 |
| Net Sales Growth(%) | 9.91 | 8.45 | 6.14 | -3.08 | -22.63 | -38.1 | 24.46 | -0.26 | -31.35 | -100 | 0 |
| EBIT Growth(%) | -16.99 | -52.42 | 21.3 | -44.79 | -225.08 | 0.35 | 58.59 | 44.97 | 5894.76 | -98.94 | 717.22 |
| PAT Growth(%) | -18.37 | -51.47 | 6.66 | -38.12 | -532.67 | 11.52 | -5.14 | -87.12 | 392.78 | -99.14 | 955.46 |
| EPS Growth(%) | -18.42 | -51.62 | 6.55 | -38.31 | -532.66 | 11.52 | -5.14 | -87.12 | 392.78 | -99.14 | 955.26 |
| Debt/Equity(x) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Ratio(x) | 3.18 | 3.18 | 2.54 | 2.56 | 1.74 | 2.43 | 1.56 | 2.66 | 17.68 | 5.15 | 11.33 |
| Quick Ratio(x) | 3.1 | 3.1 | 2.49 | 2.52 | 1.7 | 2.36 | 1.5 | 2.63 | 17.68 | 5.15 | 11.33 |
| Interest Cover(x) | 25.67 | 10.76 | 15.53 | 6.48 | -0.53 | -0.57 | -0.26 | -0.15 | 12.62 | 56.7 | 0 |
| Total Debt/Mcap(x) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 62.71 | 62.71 | 62.71 | 62.71 | 62.71 | 62.71 | 62.71 | 62.71 | 62.71 | 62.71 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0.07 | 0.07 | 0.07 | 0.07 | 0.07 | 0.07 | 0.07 | 0.07 | 0.07 | 0.07 |
| Public | 37.22 | 37.22 | 37.22 | 37.22 | 37.22 | 37.22 | 37.22 | 37.22 | 37.22 | 37.22 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 1.18 | 1.18 | 1.18 | 1.18 | 1.18 | 1.18 | 1.18 | 1.18 | 1.18 | 1.18 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1.87 | 1.87 | 1.87 | 1.87 | 1.87 | 1.87 | 1.87 | 1.87 | 1.87 | 1.87 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | — | -100% | -100% | -100% |
| Operating Profit CAGR | +400% | -23% | +20% | -10% |
| PAT CAGR | — | — | — | -4% |
| Share Price CAGR | -37% | -10% | -9% | -7% |
| ROE Average | +13% | +22% | +7% | +3% |
| ROCE Average | +15% | +26% | +15% | +8% |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 62.71 | 62.71 | 62.71 | 62.71 | 62.71 | 62.71 | 62.71 | 62.71 | 62.71 | 62.71 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0.07 | 0.07 | 0.07 | 0.07 | 0.07 | 0.07 | 0.07 | 0.07 | 0.07 | 0.07 |
| Public | 37.22 | 37.22 | 37.22 | 37.22 | 37.22 | 37.22 | 37.22 | 37.22 | 37.22 | 37.22 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 1.18 | 1.18 | 1.18 | 1.18 | 1.18 | 1.18 | 1.18 | 1.18 | 1.18 | 1.18 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1.87 | 1.87 | 1.87 | 1.87 | 1.87 | 1.87 | 1.87 | 1.87 | 1.87 | 1.87 |
* The pros and cons are machine generated.
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
Your relationship manager will connect with you shortly.